KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Research & Development (2016 - 2025)

Eli Lilly (LLY) has disclosed Research & Development for 17 consecutive years, with $3.8 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 25.76% year-over-year to $3.8 billion, compared with a TTM value of $13.3 billion through Dec 2025, up 21.34%, and an annual FY2025 reading of $13.3 billion, up 21.34% over the prior year.
  • Research & Development was $3.8 billion for Q4 2025 at Eli Lilly, up from $3.5 billion in the prior quarter.
  • Across five years, Research & Development topped out at $3.8 billion in Q4 2025 and bottomed at $1.6 billion in Q1 2022.
  • Average Research & Development over 5 years is $2.4 billion, with a median of $2.4 billion recorded in 2023.
  • The sharpest move saw Research & Development decreased 3.71% in 2022, then surged 33.62% in 2023.
  • Year by year, Research & Development stood at $1.9 billion in 2021, then increased by 7.06% to $2.0 billion in 2022, then increased by 28.38% to $2.6 billion in 2023, then rose by 17.98% to $3.0 billion in 2024, then grew by 25.76% to $3.8 billion in 2025.
  • Business Quant data shows Research & Development for LLY at $3.8 billion in Q4 2025, $3.5 billion in Q3 2025, and $3.3 billion in Q2 2025.